

ASX Release

SUDA RECEIVES \$662K R&D TAX INCENTIVE REFUND

PERTH, AUSTRALIA – 30 November 2017: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has received a refund of \$662,877 from the Australian Taxation Office under the R&D Tax Incentive for eligible expenditure for the 2017 financial year.

Commenting on the refund, Mr Stephen Carter, Chief Executive Officer of SUDA Pharmaceuticals Ltd said: "The R&D Tax Incentive provides a valuable benefit to companies such as SUDA, so that we can invest more in our OroMist® technology and pipeline of novel oral sprays. We have made good progress since our last refund, including deals signed with Pfizer Consumer Healthcare and Teva Pharmaceuticals, together with the submission of a Marketing Authorisation Application for our novel ArTiMist® sublingual anti-malarial spray with the Australian Therapeutic Goods Administration. We look forward to achieving further milestones with the support of this new R&D Tax Incentive refund."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com